CD8+ T-bet+ cells as a predominant biomarker for inclusion body myositis.
Autor: | Dzangué-Tchoupou G; Centre of Research in Myology, Sorbonne Université, INSERM, Association Institut de Myologie, UMRS 974, 75013 Paris, France. Electronic address: gaelle.dzangue-tchoupou@cea.fr., Mariampillai K; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, DHU I2B, AP-HP, INSERM, UMR 974, 75103 Paris, France., Bolko L; Centre of Research in Myology, Sorbonne Université, INSERM, Association Institut de Myologie, UMRS 974, 75013 Paris, France., Amelin D; Centre of Research in Myology, Sorbonne Université, INSERM, Association Institut de Myologie, UMRS 974, 75013 Paris, France., Mauhin W; Centre of Research in Myology, Sorbonne Université, INSERM, Association Institut de Myologie, UMRS 974, 75013 Paris, France., Corneau A; Plateforme de Cytométrie (CyPS), Sorbonne Université, UPMC Univ Paris 06, INSERM, UMR 1135, 75013, Paris, France., Blanc C; Plateforme de Cytométrie (CyPS), Sorbonne Université, UPMC Univ Paris 06, INSERM, UMR 1135, 75013, Paris, France., Allenbach Y; Centre of Research in Myology, Sorbonne Université, INSERM, Association Institut de Myologie, UMRS 974, 75013 Paris, France; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, DHU I2B, AP-HP, INSERM, UMR 974, 75103 Paris, France., Benveniste O; Centre of Research in Myology, Sorbonne Université, INSERM, Association Institut de Myologie, UMRS 974, 75013 Paris, France; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, DHU I2B, AP-HP, INSERM, UMR 974, 75103 Paris, France. |
---|---|
Jazyk: | angličtina |
Zdroj: | Autoimmunity reviews [Autoimmun Rev] 2019 Apr; Vol. 18 (4), pp. 325-333. Date of Electronic Publication: 2019 Feb 28. |
DOI: | 10.1016/j.autrev.2019.02.003 |
Abstrakt: | Background: Myositis is a heterogeneous group of muscular auto-immune diseases with clinical and pathological criteria that allow the classification of patients into different sub-groups. Inclusion body myositis is the most frequent myositis above fifty years of age. Diagnosing inclusion body myositis requires expertise and is challenging. Little is known concerning the pathogenic mechanisms of this disease in which conventional suppressive-immune therapies are inefficacious. Objectives: Our aim was to deepen our understanding of the immune mechanisms involved in inclusion body myositis and identify specific biomarkers. Methods: Using a panel of thirty-six markers and mass cytometry, we performed deep immune profiling of peripheral blood cells from inclusion body myositis patients and healthy donors, divided into two cohorts: test and validation cohorts. Potential biomarkers were compared to myositis controls (anti-Jo1-, anti-3-hydroxyl-3-methylglutaryl CoA reductase-, and anti-signal recognition particle-positive patients). Results: Unsupervised analyses revealed substantial changes only within CD8+ cells. We observed an increase in the frequency of CD8+ cells that expressed high levels of T-bet, and containing mainly both effector and terminally differentiated memory cells. The senescent marker CD57 was overexpressed in CD8+ Conclusion: Using a panel of thirty-six markers by mass cytometry, we identify an activated cell population (CD8+ (Copyright © 2019 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |